Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series

Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series

Patients with hematologic malignancies are at high risk of exacerbated condition and higher mortality from coronavirus disease 2019 (COVID-19). Bamlanivimab, casirivimab/imdevimab combination, and sotrovimab are monoclonal antibodies (mABs) that can reduce the risk of COVID-19-related hospitalizatio...

Full description

Bibliographic Details
Main Authors: Göran Ramin Boeckel, Silke Dorothea Hölscher, Christin Bürger, Torid Jacob, Carolin Krekeler, Evgenii Shumilov, Christian Reicherts, Annalen Bleckmann, Georg Lenz, Richard Vollenberg, Phil-Robin Tepasse
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Current Oncology
Subjects:
SARS-CoV-2
COVID-19
hematologic malignancies
cancer
antibody therapy
casirivimab
Online Access:https://www.mdpi.com/1718-7729/29/4/188

Internet

https://www.mdpi.com/1718-7729/29/4/188

Similar Items